BridgeBio Pharma (BBIO) Price & Analysis

Compare

1,195 Followers

BBIO Stock Chart & Stats

Day’s Range― - ―

52-Week Range$21.62 - $40.40

Previous CloseN/A

Volume379.31K

Average Volume (3M)3.09M

Market Cap

$7.61B

Enterprise Value$2.47B

Total Cash (Recent Filing)$540.60M

Total Debt (Recent Filing)$10.12M

Price to Earnings (P/E)―

Beta1.47

Next Earnings

Jul 31, 2025

EPS Estimate

-0.75

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.88

Shares Outstanding189,880,720

10 Day Avg. Volume2,755,071

30 Day Avg. Volume3,086,528

Financial Highlights & Ratios

PEG Ratio0.09

Price to Book (P/B)-0.90

Price to Sales (P/S)0.00

P/FCF Ratio-2.64

Enterprise Value/Market Cap0.32

Enterprise Value/Revenue3.14

Enterprise Value/Gross Profit20.00

Enterprise Value/Ebitda-1.45

Forecast

1Y Price Target

$60.71

Price Target Upside53.11% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering15

BridgeBio Pharma News

See All News >

Bulls Say, Bears Say

Bulls Say

Commercial StrategyAttruby's strong 1Q sales were fueled by expansion of the ATTR-CM market, high fill rate of scripts, and BBIO's differentiated commercial strategy.

Regulatory ApprovalsAcoramidis was approved as BEYONTTRA™ by the European Commission, the Japanese Ministry of Health, Labour, and Welfare (MHLW) Agency, and the United Kingdom Medicines and Healthcare Products Regulatory Agency, indicating strong regulatory support.

Sales MomentumBridgeBio continues to report encouraging sales momentum, with 2,072 unique patient prescriptions written for acoramidis by 756 physicians.

Bears Say

Competitive PressureAttruby's launch momentum in 1Q may decelerate in 2Q due to competitor Amvuttra's market entry and normalization of the script fill rate.

Market CompetitionAmvuttra's entry is expected to negatively impact Attruby's uptake as suggested by Amvuttra's spiking weekly sales and Attruby's declined average scripts per week.

Market DynamicsAttruby's launch momentum may decline due to increasing Amvuttra penetration.

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

29.25% Insiders

16.80% Mutual Funds

0.62% Other Institutional Investors

39.22% Public Companies and Individual Investors

Detailed Ownership Overview >

BBIO FAQ

What was BridgeBio Pharma Inc’s price range in the past 12 months?

BridgeBio Pharma Inc lowest stock price was $21.62 and its highest was $40.40 in the past 12 months.

What is BridgeBio Pharma Inc’s market cap?

BridgeBio Pharma Inc’s market cap is $7.61B.

When is BridgeBio Pharma Inc’s upcoming earnings report date?

BridgeBio Pharma Inc’s upcoming earnings report date is Jul 31, 2025 which is in 48 days.

How were BridgeBio Pharma Inc’s earnings last quarter?

BridgeBio Pharma Inc released its earnings results on Apr 29, 2025. The company reported -$0.88 earnings per share for the quarter, beating the consensus estimate of -$0.918 by $0.038.

Is BridgeBio Pharma Inc overvalued?

According to Wall Street analysts BridgeBio Pharma Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does BridgeBio Pharma Inc pay dividends?

BridgeBio Pharma Inc does not currently pay dividends.

What is BridgeBio Pharma Inc’s EPS estimate?

BridgeBio Pharma Inc’s EPS estimate is -0.75.

How many shares outstanding does BridgeBio Pharma Inc have?

BridgeBio Pharma Inc has 189,880,720 shares outstanding.

What happened to BridgeBio Pharma Inc’s price movement after its last earnings report?

BridgeBio Pharma Inc reported an EPS of -$0.88 in its last earnings report, beating expectations of -$0.918. Following the earnings report the stock price went up 5.327%.

Which hedge fund is a major shareholder of BridgeBio Pharma Inc?

Currently, no hedge funds are holding shares in BBIO

BridgeBio Pharma Stock Smart Score

Outperform

Fundamentals

Return on Equity

35.68%

Trailing 12-Months

Asset Growth

3.80%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

BridgeBio Pharma Inc

BridgeBio Pharma, Inc. is a biotechnology company focused on discovering, developing, and delivering transformative medicines to treat genetic diseases at their source. The company operates in the pharmaceutical and healthcare sectors, with a portfolio that includes a diverse array of drug candidates targeting diseases with high unmet need, primarily genetic disorders. BridgeBio's core products and services revolve around its robust pipeline of therapeutics designed to address conditions across oncology, cardiology, dermatology, and neurology.

BBIO Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call was largely positive with the successful launch of Attruby driving significant revenue and the strong progress of the pipeline. While there were increased SG&A expenses due to the commercial rollout, the overall impact was minimal compared to the positive developments.Read More>

BBIO Stock 12 Month Forecast

Average Price Target

$60.71

▲(53.11%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"23":"$23","96":"$96","41.25":"$41.3","59.5":"$59.5","77.75":"$77.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":95,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$95.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":60.71,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$60.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$42.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[23,41.25,59.5,77.75,96],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35.46,40.04,44.620000000000005,49.2,53.78,58.36,62.94,67.52000000000001,72.1,76.68,81.25999999999999,85.84,90.42,{"y":95,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35.46,37.402307692307694,39.34461538461539,41.286923076923074,43.22923076923077,45.17153846153846,47.113846153846154,49.05615384615385,50.99846153846154,52.940769230769234,54.88307692307693,56.82538461538462,58.76769230769231,{"y":60.71,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35.46,35.963076923076926,36.466153846153844,36.96923076923077,37.472307692307695,37.97538461538461,38.47846153846154,38.98153846153846,39.48461538461538,39.987692307692306,40.49076923076923,40.99384615384615,41.496923076923075,{"y":42,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":28.01,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.2,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.18,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.85,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.8,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.48,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.6,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.44,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.21,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.9,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.02,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.4,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.46,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >